• Caffeine: Mechanism, Research Evidence, and Workflows

  2026-09-14

  Caffeine, also known as 1,3,7-trimethylpurine-2,6-dione, is a purine alkaloid used to study adenosine signaling, energy metabolism modulation, and cancer cell line inhibition. Product and literature evidence support controlled in vitro and diet-induced obesity mouse model workflows, but model-specific results should not be treated as clinical efficacy.

• E. coli Uracil-DNA Glycosylase (UDG) Protocol

  2026-09-14

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA to support PCR product contamination elimination and DNA damage repair research. It should be used with compatible DNA substrates, not RNA or oligonucleotides shorter than six bases, and is intended only for scientific research rather than diagnostic or medical applications.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)

  2026-09-12

  This EDTA-free Protease Inhibitor Cocktail helps limit proteolysis during protein extraction and downstream Western blot, co-immunoprecipitation, pull-down, and enzyme workflows. It should be diluted at least 200-fold and empirically checked for cell, DMSO, and assay compatibility; it is not a substitute for experiment-specific validation of every protease or metalloprotease condition.

• E-64 for Reliable Cell-Based Assays

  2026-09-11

  Learn how E-64 (SKU A2576) can help laboratories distinguish cysteine-protease-dependent biology from assay artifacts in viability, proliferation, and cytotoxicity workflows. This scenario-driven guide covers concentration selection, controls, handling, interpretation, and practical product-selection criteria.

• Cy3 NHS Ester (Non-Sulfonated): Practical Protocol

  2026-09-11

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for accessible primary amines on proteins, peptides, and oligonucleotides. It is appropriate when DMSO or DMF can be tolerated, but it is not a good first choice for strictly aqueous workflows or delicate proteins that require co-solvent-free conditions.

• Dual-Action Inhibitors Reprogram p38α Dephosphorylation

  2026-09-10

  This preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also shift the activation loop into a conformation that accelerates WIP1-mediated dephosphorylation. By combining biochemical rate measurements with X-ray crystallography, the study introduces conformational control of phosphatase access as a strategy for improving kinase inhibitor function and specificity.

• D-Lin-MC3-DMA: From Silencing to Smart LNP Design

  2026-09-10

  D-Lin-MC3-DMA remains a powerful benchmark for RNA delivery, but its greatest translational value may lie in how it helps researchers build better, more predictive lipid nanoparticle programs. This article connects its endosomal escape mechanism and hepatic gene-silencing record with machine-learning-guided, cell-state-aware mRNA delivery.

• ML-Designed LNPs Reprogram Hyperactivated Microglia

  2026-09-09

  Rafiei, Shojaei, and Chau combined a 216-formulation LNP library with supervised machine learning to identify mRNA carriers that preferentially modulate inflammatory microglia. Their best formulation, HA-LNP2, delivered IL10 mRNA, reduced inflammatory markers, and reproduced activity in human iPSC-derived microglia, providing a practical framework for cell-state-aware nanoparticle design.

• Erastin B1524: Practical Ferroptosis Workflows

  2026-09-09

  Learn how Erastin (SKU B1524) can standardize ferroptosis experiments across cell-viability, ROS, and cytotoxicity workflows. This scenario-based guide connects preparation, dose selection, controls, interpretation, and vendor evaluation to published evidence and practical laboratory constraints.

• Clasto-Lactacystin β-lactone in Viral Immunity

  2026-09-08

  Clasto-Lactacystin β-lactone is more than a standard proteasome inhibitor: it is a causal perturbation tool for testing whether protein degradation controls inflammatory cell death. This article connects its irreversible mechanism to the vIRD–RIPK3 findings in orthopoxvirus research and translates that insight into assay design.

• Ouabain Assays: Separating Pump Block from Cell Fate

  2026-09-08

  Ouabain is a selective Na+/K+-ATPase inhibitor for dissecting ion transport, calcium handling, and cellular outcomes. This guide combines mechanistic pharmacology with an assay-design framework that separates direct pump inhibition from growth arrest and cell death.

• Sinapine, PLCβ3 EF Hands, and Cardiovascular Signaling

  2026-09-07

  The reference study identifies sinapine as a PLCβ3-directed inhibitor that disrupts the Gαq–PLCβ3 interaction through the PLCβ3 EF-hand region, with Asn-260 implicated in target engagement. By focusing on a pathway-specific protein–protein interaction rather than broadly inhibiting Gαq or PLC activity, the work presents a more selective strategy for limiting RAAS-associated aldosteronism and hypertension.

• How Kinase Inhibitors Tune p38α Dephosphorylation

  2026-09-07

  The referenced bioRxiv study identifies a dual-action mechanism in which selected p38α inhibitors both block kinase activity and accelerate WIP1-mediated removal of the activation-loop phosphate. Structural comparisons connect this effect to an inhibitor-stabilized activation-loop conformation, offering a framework for interpreting kinase assays and designing more selective signaling modulators.

• MHY1485 as an mTOR Probe for Pathway Dissection

  2026-09-05

  MHY1485 is an mTOR activator that can help separate mTORC1 signaling from autophagic-flux phenotypes. This article develops a mechanistic assay framework connecting pathway readouts, autophagosome behavior, and the LMP2A–mTORC1–GCNT3 axis in nasopharyngeal carcinoma research.

• Arrb2, 6-ketoLCA, and Hepatic IRI

  2026-09-04

  The reference study identifies hepatocyte β-arrestin 2, encoded by Arrb2, as an upstream regulator of 6-ketoLCA production and macrophage polarization during hepatic ischemia–reperfusion injury. By combining clinical samples, hepatocyte-directed mouse genetics, hypoxia–reoxygenation assays, and metabolomics, it connects parenchymal signaling with immune resolution and provides a framework for mechanistic ischemia–reperfusion research.

8032 records 1/536 page Next 12345 下5页 Last page